Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 1990;12(1):33–45. doi: 10.1007/BF00192680

Fulminant hepatitis

Stephen Sinclair 1,✉, Andrew Wakefield 2, Gary Levy 1
PMCID: PMC7087515  PMID: 1695027

Conclusion

In conclusion, evidence exists that cellular and humoral immune-mediated processes result in hepatic necrosis in FH. Activation of the immune coagulation system appears to be an integral part of the inflammatory process resulting in fibrin thrombi which have been demonstrated in the liver, kidneys and lungs of patients with FH. A beneficial role of PG in the treatment of FH has been demonstrated, but controlled trials are required to firmly establish the efficacy of these agents. At present liver transplantation remains the treatment of choice in selected patients with FH. Further studies of the role of the immune system in the pathogenesis of this disease are required to devise more effective therapeutic strategies.

Keywords: Hepatitis, Internal Medicine, Immune System, Liver Transplantation, Therapeutic Strategy

Abbreviations

DIC

disseminated intravascular coagulation

dmPGE2

dimethyl prostaglandin E2

ELAM

endothelial-leukocyte adhesion molecule

FH

fulminant hepatitis

HBV

hepatitis B virus

HBcAg

hepatitis B core antigen

HBsAg

hepatitis B surface antigen

HE

hepatic encephalopathy

IFN

interferon

MHC

major histocompatibility complex

MHV

murine hepatitis virus

PCA

procoagulant activity

PG

prostaglandins

TNF

tumor necrosis factor

2-5 AS

oligoadenylate synthetase

References

  • 1.Abecassis M, Falk JA, Makowka L, Dindzans VJ, Falk RE, Levy GA. 16, 16-Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest. 1987;80:881. doi: 10.1172/JCI113147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Abecassis M, Falk R, Blendis L, Falk J, Langer B, Greig P, Superina R, Strasberg S, Taylor B, Glynn M, Levy G. Treatment of fulminant hepatic failure with a continuous infusion of Prostin VR (PGE1) (Abstract) Hepatology. 1987;7:1104. [Google Scholar]
  • 3.Alp MH, Hickman R. Plasmaphoresis, charcoal and resin perfusion in experimental porcine hepatic failure. Dig Dis Sci. 1986;31:181. doi: 10.1007/BF01300706. [DOI] [PubMed] [Google Scholar]
  • 4.Alp MH, Hickman R. The effect of prostaglandins, branched-chain amino acids and other drugs on the outcome of experimental acute porcine hepatic failure. J Hepatol. 1987;4:99. doi: 10.1016/s0168-8278(87)80016-8. [DOI] [PubMed] [Google Scholar]
  • 5.Araki H, Lefer AM. Cytoprotective actions of prostacyclin during hypoxia in the isolated perfused cat liver. Am J Physiol. 1980;238:H176. doi: 10.1152/ajpheart.1980.238.2.H176. [DOI] [PubMed] [Google Scholar]
  • 6.Auslander MO, Gitnick GL. Vigorous medical management of acute fulminant hepatitis. Arch Intern Med. 1977;137:599. [PubMed] [Google Scholar]
  • 7.Bal V, Amin SN, Rath S, Kamat SA, Zuckerman AJ, Marathe SN, Kamat RS. Virological markers and antibody responses in fulminant viral hepatitis. J Med Virol. 1987;23:75. doi: 10.1002/jmv.1890230109. [DOI] [PubMed] [Google Scholar]
  • 8.Bernuau J, Goudeau A, Poynard T, Dubois F, Lesage G, Yvonnet B, Degott C, Bezeaud A, Rueff B, Benhamou JP. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6:648. doi: 10.1002/hep.1840060417. [DOI] [PubMed] [Google Scholar]
  • 9.Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986;6:97. doi: 10.1055/s-2008-1040593. [DOI] [PubMed] [Google Scholar]
  • 10.Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA., Jr Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med. 1984;160:618. doi: 10.1084/jem.160.2.618. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985;76:2003. doi: 10.1172/JCI112200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, Gimbrone MA. Interleukin 1 activation of vascular endothelium: effects on procoagulant activity and leukocyte adhesion. Am J Pathol. 1985;121:394. [PMC free article] [PubMed] [Google Scholar]
  • 13.Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA. 1986;83:4533. doi: 10.1073/pnas.83.12.4533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bevilacqua MP, Schleef RR, Gimbrone MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured human vascular endothelium by interleukin 1. J Clin Invest. 1986;78:587. doi: 10.1172/JCI112613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Bianchi L. Necroinflammatory liver diseases. Semin Liver Dis. 1986;6:185. doi: 10.1055/s-2008-1040602. [DOI] [PubMed] [Google Scholar]
  • 16.Bianchi L, Gudat F. Immunopathology of hepatitis B. In: Popper H, Schaffner F, editors. Progess in liver diseases. New York: Grune & Stratton; 1979. pp. 371–392. [PubMed] [Google Scholar]
  • 17.Bihari DJ, Gimson AES, Williams R. Cardiovascular, pulmonary and renal complications of fulminant hepatic failure. Semin Liver Dis. 1986;6:119. doi: 10.1055/s-2008-1040595. [DOI] [PubMed] [Google Scholar]
  • 18.Bismuth H, Samuel D, Gugenheim J, Castaing D, Bernuau J, Rueff B, Benhamou JP. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med. 1987;107:337. doi: 10.7326/0003-4819-107-2-337. [DOI] [PubMed] [Google Scholar]
  • 19.Bourne HR, Lichtenstein LM, Melmon KL, Henney CS, Weinstein Y, Shearer GM. Modulation of inflammation and immunity by cyclic AMP. Science. 1974;184:19. doi: 10.1126/science.184.4132.19. [DOI] [PubMed] [Google Scholar]
  • 20.Brass EP, Alford CE, Garrity MJ. Inhibition of glucagon-stimulated cAMP accumulation and fatty acid oxidation by E-series prostaglandins in isolated rat hepatocytes. Biochim Biophys Acta. 1987;930:122. doi: 10.1016/0167-4889(87)90164-9. [DOI] [PubMed] [Google Scholar]
  • 21.Chisari FV, Bieber MS, Josepho CA, Xavier C, Anderson DS. Functional properties of lymphocyte subpopulations in hepatitis B virus infection II. Cytotoxic effector cell killing of targets that naturally express hepatitis B surface antigen and liver-specific lipoprotein. J Immunol. 1981;126:45. [PubMed] [Google Scholar]
  • 22.Chisari FV, Castle KL, Xavier C, Anderson DS. Functional properties of lymphocyte subpopulations in hepatitis B virus infection I. Suppressor cell control of T lymphocyte responsiveness. J Immunol. 1981;126:3844. [PubMed] [Google Scholar]
  • 23.Cole EH, Levy GA. Interaction of monocytes with vascular endothelium. In: Asherson G, editor. The human monocyte. London: Academic Press; 1989. pp. 353–360. [Google Scholar]
  • 24.Davis DC, Potter WZ, Jollow DJ, Mitchell JR. Species differences in hepatic glutathione depletion, covalent binding and hepatic necrosis after acetaminophen. Life Sci. 1974;14:2099. doi: 10.1016/0024-3205(74)90092-7. [DOI] [PubMed] [Google Scholar]
  • 25.Davis GL, Hoofnagle JH. Interferon in viral hepatitis: role in pathogenesis and treatment. Hepatology. 1986;6:1038. doi: 10.1002/hep.1840060537. [DOI] [PubMed] [Google Scholar]
  • 26.Dindzans VJ, Skamene E, Levy GA. Susceptibility/resistance to mouse hepatitis virus strain 3 and macrophage procoagulant activity are genetically linked and controlled by two non-H-2-linked genes. J Immunol. 1986;137:2355. [PubMed] [Google Scholar]
  • 27.Dixit V, Chang TMS. Effects of prostaglandin E2 on the survival time of fulminant hepatic failure rats. Int J Artif Organs. 1982;5:388. [PubMed] [Google Scholar]
  • 28.Dixit V, Chang TMS. Preliminary report on effects of prostaglandin E2 on brain edema in fulminant hepatic failure rats. Int J Artif Organs. 1985;8:55. [PubMed] [Google Scholar]
  • 29.Dixit V, Chang TMS. Effects of prostaglandin E2 on brain edema and liver histopathology in a galactosamine-induced fulminant hepatic failure rat model. Biomater Artif Cells Artif Organs. 1987;15:559. doi: 10.3109/10731198709117553. [DOI] [PubMed] [Google Scholar]
  • 30.Dudley FJ, Fox RA, Sherlock S. Cellular immunity and hepatitis-associated, Australia antigen liver disease. Lancet. 1972;I:723. doi: 10.1016/s0140-6736(72)90234-6. [DOI] [PubMed] [Google Scholar]
  • 31.Eggink HF, Houthoff HJ, Huitema S, Walters G, Poppema S, Gips CH. Cellular and humoral immune reactions in chronic active liver disease II Lymphocyte subsets and viral antigens in liver biopsies of patients with acute and chronic hepatitis B. Clin Exp Immunol. 1984;56:121. [PMC free article] [PubMed] [Google Scholar]
  • 32.Esmon CT. The regulation of natural anticoagulant pathways. Science. 1987;235:1348. doi: 10.1126/science.3029867. [DOI] [PubMed] [Google Scholar]
  • 33.European Association for the Study of Liver Randomized trial of steroid therapy in acute liver failure. Gut. 1979;20:620. doi: 10.1136/gut.20.7.620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Fantone JC, Kunkel SL, Ward PA, Zurier RB. Suppression by prostaglandin E1 of vascular permeability induced by vasoactive inflammatory mediators. J Immunol. 1980;125:2591. [PubMed] [Google Scholar]
  • 35.Franco A, Barnaba V, Natali P, Galsano C, Musca A, Balsano F. Expression of class I and class II major histocompatibility complex antigens on human hepatocytes. Hepatology. 1988;8:449. doi: 10.1002/hep.1840080302. [DOI] [PubMed] [Google Scholar]
  • 36.Galbraith RM, Eddleston AL, Williams R. Fulminant hepatic failure in leukemia and choriocarcinoma related to withdrawal of cytotoxic drug therapy. Lancet. 1975;II:528. doi: 10.1016/s0140-6736(75)90897-1. [DOI] [PubMed] [Google Scholar]
  • 37.Gimbrone MA. Vascular Endothelium and Atherosclerosis. In: Moore S, editor. Vascular Injury and Atherosclerosis. New York: Dekker; 1981. pp. 25–45. [Google Scholar]
  • 38.Gimson AES, White YS, Eddleston ALWF, Williams R. Clinical and prognostic differences in fulminant hepatitis type A, B and non-A, non-B. Gut. 1983;24:1194. doi: 10.1136/gut.24.12.1194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Gregory PB, Knauer CM, Kempson RL, Miller R. Steroid therapy in severe viral hepatitis. A double-blind, randomized trial of methyl-prednisolone versus placebo. N Engl J Med. 1976;294:681. doi: 10.1056/NEJM197603252941301. [DOI] [PubMed] [Google Scholar]
  • 40.Ham EA, Soderman DD, Zanetti ME, Dougherty HW, McCauley E, Kuehl FA. Inhibition by prostaglandins of leukotriene B4 release from activated neutrophils. Proc Natl Acad Sci USA. 1983;80:4349. doi: 10.1073/pnas.80.14.4349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Hasegawa K, Yamauchi K, Furukawa T, Obata H. Dual color fluorescence analysis of peripheral T cell subsets in hepatitis B virus-induced liver disease. Hepatology. 1988;8:1134. doi: 10.1002/hep.1840080528. [DOI] [PubMed] [Google Scholar]
  • 42.Hopf U, Meyer Zum Buschenfelde, Freudenberg J. Liver specific antigens of different species II. Localization of a membrane antigen at cell surface of isolated hepatocytes. Clin Exp Immunol. 1974;16:117. [PMC free article] [PubMed] [Google Scholar]
  • 43.Ikeda T, Lever AML, Thomas HC. Evidence for a deficiency of interferon production in patients with chronic hepatitis B virus infection acquired in adult life. Hepatology. 1986;6:962. doi: 10.1002/hep.1840060525. [DOI] [PubMed] [Google Scholar]
  • 44.Ise I, Tsuda F, Aihara S, Machida A, Takai E, Miyamoto H, Akahane Y, Miyakawa Y, Mayumi M. Antibodies to translation products of the pre-S1 and pre-S2 regions of the envelope gene of hepatitis B virus in fulminant hepatitis B. Hepatology. 1988;8:1089. doi: 10.1002/hep.1840080518. [DOI] [PubMed] [Google Scholar]
  • 45.Kakumu S, Hara T, Goji H, Sakamoto N. Lymphocyte cytotoxicity against Chang liver cells in chronic active hepatitis. Cell Immunol. 1978;36:46. doi: 10.1016/0008-8749(78)90249-6. [DOI] [PubMed] [Google Scholar]
  • 46.Kato Y, Noda Y, Unoura M, Tanaka N, Kobayashi K, Hattori N, Hatano K, Kobayashi S. Effect of exogenous mouse interferon on murine fulminant hepatitis induced by mouse hepatitis virusd type 2. Dig Dis Sci. 1986;31:177. doi: 10.1007/BF01300705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Lands WEM. The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol. 1979;41:633. doi: 10.1146/annurev.ph.41.030179.003221. [DOI] [PubMed] [Google Scholar]
  • 48.Lefer AM. Leukotrienes as mediators of ischemia and shock. Biochem Pharmacol. 1986;35:123. doi: 10.1016/0006-2952(86)90502-2. [DOI] [PubMed] [Google Scholar]
  • 49.Lengyel P. Biochemistry of interferons and their actions. Annu Rev Biochem. 1982;51:251. doi: 10.1146/annurev.bi.51.070182.001343. [DOI] [PubMed] [Google Scholar]
  • 50.Levin S, Hahn T. Interferon system in acute viral hepatitis. Lancet. 1982;I:592. doi: 10.1016/s0140-6736(82)91751-2. [DOI] [PubMed] [Google Scholar]
  • 51.Levy GA, Chisari FV. The immunopathogenesis of chronic HBV induced liver disease. Springer Semin Immunopathol. 1981;3:439. doi: 10.1007/BF01951492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Levy GA, Cole EH. The monocyte and disseminated intravascular coagulation. In: Asherson G, editor. The human monocyte. London: Academic Press; 1989. pp. 429–438. [Google Scholar]
  • 53.Levy GA, MacPhee PJ, Fung LS, Fisher MM, Rappaport AM. The effect of mouse hepatitis viras infection on the microcirculation of the liver. Hepatology. 1983;3:964. doi: 10.1002/hep.1840030614. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Levy GA, MacPhee PJ, Fung LS, Fisher MM, Rappaport AM. The effects of mouse hepatitis virus type 3 on the microcirculation of the liver in inbred strains of mice. Adv Exp Med Biol. 1984;173:397. doi: 10.1007/978-1-4615-9373-7_45. [DOI] [PubMed] [Google Scholar]
  • 55.MacPhee PJ, Dindzans VJ, Fung LS, Levy GA. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology. 1985;5:649. doi: 10.1002/hep.1840050422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.MacPhee PJ, Schmidt EE, Keown PA, Groom AC. Microcirculatory changes in livers of mice infected with murine hepatitis viras. Evidence from microcorrosion casts and measurements of red cell velocity. Microvasc Res. 1988;36:140. doi: 10.1016/0026-2862(88)90014-3. [DOI] [PubMed] [Google Scholar]
  • 57.Maier RV, Hahnel GB. Microthrombosis during endotoxemia: potential role of hepatic versus alveolar macrophages. J Surg Res. 1984;36:362. doi: 10.1016/0022-4804(84)90112-4. [DOI] [PubMed] [Google Scholar]
  • 58.Marinovich M, Flaminio LM, Papagni M, Galli CL. Evaluation of the cytoprotective effect of natural and synthetic prostaglandins in CCl4-induced liver cell damage. In: Samuelsson B, Paoletti R, Ramwell PW, editors. Advances in prostaglandin, thromboxane and leukotriene research. New York: Raven Press; 1987. p. 1094. [PubMed] [Google Scholar]
  • 59.Massa PT, Dorries R, ter Meulen V. Viral particles induce Ia antigen expression on astrocytes. Nature. 1986;320:543. doi: 10.1038/320543a0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Mathiesen LR, Skinoj P, Nielsen JO, Purcell RH, Wong D, Ranek L. Hepatitis type A, B and non-A non-B in fulminant hepatitis. Gut. 1979;21:72. doi: 10.1136/gut.21.1.72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.McCaul TF, Fagan EA, Tovey G, Portmann B, Williams R, Zuckerman AJ. Fulminant hepatitis an ultrastractural study. J Hepatol. 1986;368:276. doi: 10.1016/s0168-8278(86)80087-3. [DOI] [PubMed] [Google Scholar]
  • 62.Meyer Zum Buschenfelde KH, Hopf V. Studies on the pathogenesis of experimental chronic active hepatitis in rabbits I. Induction of the disease and protective effect of allogeneic liver specific proteins. Br J Exp Pathol. 1974;55:498. [PMC free article] [PubMed] [Google Scholar]
  • 63.Meyer Zum Buschenfelde KH, Hutteroth TH, Arnold W, Hopf U. Immunologie liver injury: the role of hepatitis B viral antigens and liver membrane antigens as targets. In: Popper H, Schaffner F, editors. Progess in liver diseases. New York: Grune & Stratton; 1979. pp. 407–000. [PubMed] [Google Scholar]
  • 64.Milazzo F, Galli M, Fassio PG, Cargnel A, Pugliese A, Tovo PA, Vigevani GM, Esposito R, Lazzarin A, Caredda F, Almaviva M, Gavazzeni G, Perna MC, Crocchiolo P, Moroni M. Attempted treatment of fulminant viral hepatitis with human fibroblast interferon. Infection. 1985;13:130. doi: 10.1007/BF01642872. [DOI] [PubMed] [Google Scholar]
  • 65.Mizoguchi Y, Tsutsui H, Miyajima K, Sakagami Y, Seki S, Kobayashi K, Yamamoto S, Morisawa S. The protective effects of prostaglandin E1 in an experimentaL massive hepatic cell necrosis model. Hepatology. 1987;7:1184. doi: 10.1002/hep.1840070603. [DOI] [PubMed] [Google Scholar]
  • 66.Mondelli M, Eddleston ALWF. Mechanisms of liver cell injury in acute and chronic hepatitis B. Semin Liver Dis. 1984;4:47. doi: 10.1055/s-2008-1040645. [DOI] [PubMed] [Google Scholar]
  • 67.Mori W, Naoto A, Shiga J. Acute hepatic cell necrosis experimentally produced by viral agents in rabbits. Am J Pathol. 1981;103:31. [PMC free article] [PubMed] [Google Scholar]
  • 68.Mori W, Machinami R, Shiga J, Taguchi T, Tanaka K, Fukusato T, Hasegawa A, Aoki N, Narita T, Kikuchi F, Kodama T, Irie H, Oka T, Yoshimura A, Aoyama H. A pathological study of fulminant hepatic disease. Acta Pathol Jpn. 1984;34:727. doi: 10.1111/j.1440-1827.1984.tb07601.x. [DOI] [PubMed] [Google Scholar]
  • 69.Mori W, Shiga J, Irie H. Schwartzman reaction as a pathogenetic mechanism in fulminant hepatitis. Semin Liver Dis. 1986;6:267. doi: 10.1055/s-2008-1040609. [DOI] [PubMed] [Google Scholar]
  • 70.Morris A, Cooley M, Blackmon M. The interaction of interferon with the immune response. J Hepatol. 1986;3:5161. doi: 10.1016/s0168-8278(86)80116-7. [DOI] [PubMed] [Google Scholar]
  • 71.Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986;163:740. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Nawroth PP, Stern DM. A pathway of coagulation on endothelial cells. J Cell Biochem. 1985;28:253. doi: 10.1002/jcb.240280403. [DOI] [PubMed] [Google Scholar]
  • 73.Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin-1 induces endothelial cell procoagulant while suppressing cell surface anticoagulant activity. Proc Natl Acad Sci USA. 1986;83:3460. doi: 10.1073/pnas.83.10.3460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Nawroth PP, Handley D, Stern DM. The multiple levels of endothelial cell-coagulation factor interactions. Clin Haematol. 1986;15:293. [PubMed] [Google Scholar]
  • 75.Noda Y, Hughes RD, Williams R. Effect of prostacyclin (PGI2) and a prostaglandin analogue BW 245C on galactosamine-induced hepatic necrosis. J Hepatol. 1986;2:53. doi: 10.1016/s0168-8278(86)80008-3. [DOI] [PubMed] [Google Scholar]
  • 76.Nowoslawski A. Hepatitis B virus-induced immune complex disease. In: Popper H, Schaffner F, editors. Progress in Liver Diseases. New York: Grune & Stratum; 1979. pp. 393–406. [PubMed] [Google Scholar]
  • 77.Ogawa M, Mori T, Mori Y, Ueda S, Yoshida H, Kata I, Iesato K, Wakashin Y, Wakashin M, Okuda K. Inhibitory effects of prostaglandin E1 on T cell mediated cytotoxicity against isolated mouse liver cells. Gastroenterology. 1988;94:1024. doi: 10.1016/0016-5085(88)90562-8. [DOI] [PubMed] [Google Scholar]
  • 78.O'Grady JJ, Williams R, Calne RY. Transplantation in fulminant hepatic failure. Lancet. 1986;II:1227. doi: 10.1016/s0140-6736(86)92247-6. [DOI] [PubMed] [Google Scholar]
  • 79.O'Grady JJ, Gimson AES, O'Brien CJ, Pucknell A, Hughes RD, Williams R. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology. 1988;94:1186. doi: 10.1016/0016-5085(88)90011-x. [DOI] [PubMed] [Google Scholar]
  • 80.Onji M, Kumon I, Kanaoka M, Horiike N, Ohta Y. Identification of intrahepatic lymphocyte subpopulations in patients with fulminant hepatitis by the immunoenzymatic technique, using monoclonal antibodies. Hepatogastroenterology. 1987;34:141. [PubMed] [Google Scholar]
  • 81.Peleman RR, Gavaler JS, Van Thiel DH, Esquivel C, Gordon R, Iwatsuki S, Starzl TE. Orthotopic liver transplantation for acute and subacute hepatic failure in adults. Hepatology. 1987;7:484. doi: 10.1002/hep.1840070312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 82.Rakela J. Fulminant hepatitis: treatment or management? Mayo Clin Proc. 1983;58:690. [PubMed] [Google Scholar]
  • 83.Rakela J, Lange SM, Ludwig J, Baldus WP. Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc. 1985;60:289. doi: 10.1016/s0025-6196(12)60534-5. [DOI] [PubMed] [Google Scholar]
  • 84.Rappaport RS, Dodge GR. Prostaglandin E inhibits the production of human interleukin 2. J Exp Med. 1982;155:943. doi: 10.1084/jem.155.3.943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 85.Redeker AG, Schweitzer IL, Yamahiro HS. Randomization of corticosteroid therapy in fulminant hepatitis. N Engl J Med. 1976;254:728. doi: 10.1056/NEJM197603252941315. [DOI] [PubMed] [Google Scholar]
  • 86.Robert A, Ruwart MJ. Effects of prostaglandins on the digestive system. In: Lee JB, editor. Prostaglandins. New York: North Holland; 1982. pp. 113–176. [Google Scholar]
  • 87.Schultz RM, Kleinschmidt WJ. Functional identity between murine gamma interferon and macrophage activating factor. Nature. 1983;305:239. doi: 10.1038/305239a0. [DOI] [PubMed] [Google Scholar]
  • 88.Sherker AH, Levy GA (1990) New therapeutic strategies for chronic hepatitis. Curr Top Gastroenterol (in press)
  • 89.Sinclair SB, Greig PD, Blendis LM, Abecassis M, Roberts EA, Phillips MJ, Cameron R, Levy GA. Biochemical and clinical response to fulminant viral hepatitis to administration of Prostaglandin E: a preliminary report. J Clin Invest. 1989;84:1063. doi: 10.1172/JCI114268. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 90.Snyder DS, Beller DI, Unanue ER. Prostaglandins modulate macrophage Ia expression. Nature. 1982;299:163. doi: 10.1038/299163a0. [DOI] [PubMed] [Google Scholar]
  • 91.Steiber AC, Ambrosino G, Van Thiel D, Iwatsuki S, Starzl TE. Orthotopic liver transplantation for fulminant and subacute hepatic failure. Gastroenterol Clin N Am. 1988;17:157. [PMC free article] [PubMed] [Google Scholar]
  • 92.Stewart WE II, editor. The interferon system. Berlin Heidelberg New York, New York: Springer; 1979. pp. 1–42. [Google Scholar]
  • 93.Suzumura A, Lavi E, Weiss SR, Silberg DH. Coronavirus infection induces H-2 antigen expression on oligodendrocytes and astrocytes. Sciences. 1986;232:991. doi: 10.1126/science.3010460. [DOI] [PubMed] [Google Scholar]
  • 94.Thomas HC, Lok ASF. The immunopathology of autoimmune and hepatitis B virus-induced chronic hepatitis. Semin Liver Dis. 1984;4:36. doi: 10.1055/s-2008-1040644. [DOI] [PubMed] [Google Scholar]
  • 95.Thomas HC, Shipton U, Montano L. The HLA system: its relevance to the pathogenesis of liver disease. In: Popper H, Schaffner F, editors. Progess in liver diseases. New York: Grune & Stratton; 1979. pp. 517–527. [PubMed] [Google Scholar]
  • 96.Thomas HC, Pignatelli M, Scully LJ. Viruses and immune reactions in the liver. Scand J Gastroenterol. 1985;114:105. doi: 10.3109/00365528509093771. [DOI] [PubMed] [Google Scholar]
  • 97.Tiegs G, Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol. 1988;37:2569. doi: 10.1016/0006-2952(88)90248-1. [DOI] [PubMed] [Google Scholar]
  • 98.Trepo CG, Motin RJ, Trepo D, Sepetjian M, Prince AM. Hepatitis B antigen (HBsAg) and/or antibodies (anti-HBs and anti-HBc) in fulminant hepatitis: pathogenic and prognostic significance. Gut. 1976;17:10. doi: 10.1136/gut.17.1.10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Trey C. The fulminant hepatic failure surveillance study brief review of the effects of presumed etiology and age of survival. Can Med Assoc. 1972;106:525. [PMC free article] [PubMed] [Google Scholar]
  • 100.Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progess in liver diseases. New York: Grune & Stratton; 1970. pp. 282–298. [PubMed] [Google Scholar]
  • 101.Tripp CS, Wyche A, Unanue ER, Needleman P. The functional significance of the regulation of marcophage Ia expression by endogenous arachidonate metabolites in vitro. J Immunol. 1986;137:3915. [PubMed] [Google Scholar]
  • 102.Tygstrup N, Ranek L. Assessment of prognosis in fulminant hepatic failure. Semin Liver Dis. 1986;6:129. doi: 10.1055/s-2008-1040596. [DOI] [PubMed] [Google Scholar]
  • 103.Woolf IL, El Sheikh N, Cullens H, Lee WM, Eddleston ALWF, Williams R, Zuckerman AJ. Enhanced HBsAb production in pathogenesis of fulminant viral hepatitis type B. Br Med J. 1976;2:669. doi: 10.1136/bmj.2.6037.669. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 104.Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocyte choriomeningitis within a syngeneic or semiallogeneic system. Nature. 1974;248:702. doi: 10.1038/248701a0. [DOI] [PubMed] [Google Scholar]

Articles from Springer Seminars in Immunopathology are provided here courtesy of Nature Publishing Group

RESOURCES